SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

TRINITY BIOTECH PLC (TRIB) (CIK 0000888721)
Date: Jan. 27, 2026 · CIK: 0000888721 · Accession: 0000000000-26-000840

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-292753

Date
January 20, 2026
Author
Division of
Form
UPLOAD
Company
TRINITY BIOTECH PLC (TRIB) (CIK 0000888721)

Letter

Re: Trinity Biotech plc Registration Statement on Form F-1 Filed January 15, 2026 File No. 333-292753 Dear John Gillard:

January 20, 2026

John Gillard Chief Executive Officer Trinity Biotech plc IDA Business Park Bray, County Wicklow, A98 H5C8, Ireland

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Mary Brown, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                           January 20, 2026

John Gillard
Chief Executive Officer
Trinity Biotech plc
IDA Business Park
Bray, County Wicklow,
A98 H5C8,
Ireland

        Re: Trinity Biotech plc
            Registration Statement on Form F-1
            Filed January 15, 2026
            File No. 333-292753
Dear John Gillard:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tim Buchmiller at 202-551-3635 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Mary Brown, Esq.
</TEXT>
</DOCUMENT>